

**APC anti-mouse/human CD11b**

**Catalog # / Size:** 1106060 / 100 µg  
1106055 / 25 µg

**Clone:** M1/70

**Isotype:** Rat IgG2b, κ


**Immunogen:** C57BL/10 splenocytes

**Reactivity:** Human

**Preparation:** The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions. The solution is free of unconjugated APC and unconjugated antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

**Concentration:** 0.2



C57BL/6 mouse bone marrow cells were stained with CD11b (clone M1/70) APC (filled histogram) or rat IgG2b, κ APC isotype control (open histogram) (gated on total cells).

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 microg per million cells in 100 microL volume. It is recommended that the reagent be titrated for optimal performance for each application.

**Application Notes:** Additional reported applications (for relevant formats of this clone) include: immunoprecipitation<sup>1,4</sup>, *in vitro* blocking<sup>3,9,12</sup>, depletion<sup>2,8</sup>, immunofluorescence microscopy<sup>6,7,10</sup>, and immunohistochemistry of acetone-fixed frozen sections<sup>5,11-13</sup> and paraffin sections<sup>28</sup>. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 101231). For *in vivo* studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 101248) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/microg).

- Application References:**
1. Springer T, *et al.* 1978. *Eur. J. Immunol.* 8:539. (IP)
  2. Ault K and Springer T. 1981. *J. Immunol.* 126:359. (Deplete)
  3. Springer TA, *et al.* 1982. *Immunolet. Rev.* 68:171. (Block)
  4. Ho MK and Springer TA. 1983. *J. Biol. Chem.* 258:2766. (IP)
  5. Flotte TJ, *et al.* 1983. *Am. J. Pathol.* 111:112. (IHC)
  6. Noel GJ, *et al.* 1990. *J. Clin. Invest.* 85:208. (IF)
  7. Allen LA and Aderem A. 1996. *J. Exp. Med.* 184:627 (IF)
  8. D'Amico A and Wu L. 2003. *J. Exp. Med.* 198:293. (Deplete)
  9. Brickson SJ, *et al.* 2003. *Appl Physiol.* 95:969. (Block)
  10. Clatworthy MR and Smith KG. 2004. *J. Exp. Med.* 199:717. (IF)
  11. Hata H, *et al.* 2004. *J. Clin. Invest.* 114:582. (IHC)
  12. Zhang Y, *et al.* 2002. *J. Immunol.* 168:3088. (IHC)
  13. Iwasaki A and Kelsall BL. 2001. *J. Immunol.* 166:4884 (IHC, FC)
  14. Tailleux L. 2003. *J. Exp. Med.* 197:121. (Block, FC)
  15. Olver S, *et al.* 2006. *Cancer Research* 66:571. (FC)
  16. Tan SL, *et al.* 2006. *J. Immunol.* 176:2872. (FC) [PubMed](#)
  17. Ponomarev ED, *et al.* 2006. *J. Immunol.* 176:1402. (FC)

For research use only. Not for diagnostic use. Not for resale. Sony Biotechnology Inc. will not be held responsible for patent infringement or other violations that may occur with the use of our products.

Sony Biotechnology Inc. 1730 North First Street, San Jose, CA 95112 [www.sonybiotechnology.com](http://www.sonybiotechnology.com)

18. Dzhagalov I, *et al.* 2007. *Blood* 109:1620. (FC)
  19. Fazilleau N, *et al.* 2007. *Nature Immunol.* 8:753.
  20. Rasmussen JW, *et al.* 2006. *Infect. Immun.* 74:6590. [PubMed](#)
  21. Napimoga MH, *et al.* 2008. *J. Immunol.* 180:609. [PubMed](#)
  22. Elqaraz-Carmon V, *et al.* 2008. *J. Lipid. Res.* 49:1894. [PubMed](#)
  23. Kim DD, *et al.* 2008. *Blood* 112:1109. [PubMed](#)
  24. Guo Y, *et al.* 2008. *Blood* 112:480. [PubMed](#)
  25. Norian LA, *et al.* 2009. *Cancer Res.* 69:3086. (FC) [PubMed](#)
  26. Baumgartner CK, *et al.* 2010. *J. Immunol.* 184:573. [PubMed](#)
  27. Charles N, *et al.* 2010. *Nat. Med.* 16:701. (FC) [PubMed](#)
  28. Whiteland J, *et al.* 1995. *J. Histochem. Cytochem.* 43:313. (IHC)
  29. Iwata-Yoshikawana N, *et al.* 2014. *J Virol.* 88:8597. [PubMed](#)
  30. Chuang HC, *et al.* 2014. *Nat Commun.* 5:4602. [PubMed](#)
  31. Zaslona Z, *et al.* 2014. *J Immunol.* 193:4245. [PubMed](#)
  32. Castiglioni A, *et al.* 2015. *PLoS One.* 10:128094. [PubMed](#)
- 

**Description:** CD11b is a 170 kD glycoprotein also known as  $\alpha$ M integrin, Mac-1  $\alpha$  subunit, Mol, CR3, and Ly-40. CD11b is a member of the integrin family, primarily expressed on granulocytes, monocytes/macrophages, dendritic cells, NK cells, and subsets of T and B cells. CD11b non-covalently associates with CD18 ( $\beta$ 2 integrin) to form Mac-1. Mac-1 plays an important role in cell-cell interaction by binding its ligands ICAM-1 (CD54), ICAM-2 (CD102), ICAM-4 (CD242), iC3b, and fibrinogen.

**Antigen References:** 1. Barclay A, *et al.* 1997. The Leukocyte Antigen FactsBook Academic Press.  
2. Springer TA. 1994. *Cell* 76:301.  
3. Coxon A, *et al.* 1996. *Immunity* 5:653.